Latest News
Sequella Licenses Rights to Commercialize SQ109 for Tuberculosis in Russia and Commonwealth of Independent States
Release
Sequella Awarded $4.6 million in New NIH Grants to Expand Anti-Infectives Pipeline
Release
Thomson Reuters names SQ109 as one of the top five most promising drugs entering phase 2 Clinical Trials
Article
John H. Friedman of Easton Capital Investment Group Joins Sequella Board of Directors
Press Release
Sequella Files IND and Receives FDA Go-ahead for Phase 2 Trial of SQ109 in Helicobacter pylori-associated Duodenal Ulcers
Press Release
Welcome to Sequella
Sequella is a clinical stage antiinfectives company focused on commercializing improved treatments for serious infectious diseases. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat infectious disease threats with significant market opportunity.